La Jolla, CA – DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing novel treatment approaches to overcome the barriers of drug delivery in solid tumors, announced today that the United States Patent and Trademark Office (USPTO) has issued a new patent related to CendR peptides, further strengthening the company’s intellectual property portfolio beyond the already granted composition of matter patents. U.S. Patent No. 10370245B2 (‘Methods and compositions related to peptides and proteins with c-terminal elements’) has 183 claims and an adjusted expiry in November 2030. The patent is already active in Europe, Japan and China.
“This new patent that provides broad coverage on all peptides with CendR element ensures a robust intellectual property position around the CEND-1 platform technology and the claims granted in this particular patent exemplify the novel mechanistic approach of our science” said Harri Jarvelainen, Chief Operating Officer of DrugCendR Inc. “This development becomes more and more important as we progress with our clinical trial in patients with metastatic pancreatic cancer and prepare to publish the results at a major upcoming scientific meeting next year”.
La Jolla, CA, August 5, 2019 — DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr. Daniel Von Hoff will be a clinical advisor to the company. In this role, Dr. Von Hoff will guide the company with its clinical development programs.
Dr. Daniel Von Hoff is Physician in Chief, Distinguished Professor at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. Dr. Von Hoff has conducted more than 200 clinical trials to date and his clinical trial work has led to the approval of 3 of the 4 drugs approved by the FDA for treatment of patients with advanced pancreatic cancer, including the gemcitabine and Abraxane® combination therapy. The new treatment approaches he has helped to pioneer have helped tens of thousands of patients with breast, ovarian, prostate, colon, leukemia, skin (advanced basal cell carcinoma) and pancreatic cancer today.
“I am very pleased to be supporting DrugCendR at an especially exciting time in the development program for CEND-1,” said Dr. Von Hoff, adding “Any new therapy that could offer significant benefit to hard-to-treat solid tumors in patients is a welcome lead.”
Event: ESMO European Society for Medical Oncology
Dates: Sep 27, 2019 – Oct 1, 2019
Location: Barcelona, Spain
Event: Bionetwork 2019
Dates: Oct 23 – 25, 2019
Location: The Ritz-Carlton Laguna Niguel, CA
Event: BIO Europe 2019
Dates: Nov 11–13, 2019
Location: Hamburg, Germany
Event: JP Morgan 38th Annual Healthcare Conference
Dates: Jan 13-16, 2020
Location: San Francisco
For more information.
RECENT NEWS & RESOURCES
FEB 9
More details here: http://biocomglobalpartnering.org/.
JAN 31
La Jolla, CA (January 31, 2019) – DrugCendR Inc., a clinical-stage biopharmaceutical company dedicated to developing next generation cancer therapies designed to overcome the barriers of drug delivery in solid tumors, reported today positive progress with its ongoing pancreatic cancer clinical trial. In addition, the lead program received orphan-drug designation from the US Food and Drug administration (FDA) in pancreatic cancer. The company also announced a new member of board of directors.
The ongoing clinical trial in metastatic pancreatic cancer patients (CEND1-001, Clinical trial reference NCT03517176) has been accruing patients rapidly – the first Phase 2a -type expansion cohort for early efficacy is now open. The study is expected to be fully enrolled with at least 30 patients in the second quarter of 2019. The early results are reportedly encouraging, with high response rates as well as favorable safety profile, with no dose-limiting toxicities. “The progress with the pancreatic cancer trial has exceeded our expectations” said Harri Jarvelainen, Chief Operating Officer of DrugCendR Inc. “Our near term goal is to validate the CEND-1 platform technology in multiple indications so clinicians can treat patients with cancers with high unmet medical need more effectively.”
Receiving the FDA orphan drug designation was also announced today. It is a significant development milestone as it can facilitate the future development through several benefits such as tax credits for qualified clinical trials costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval. The FDA grants orphan drug designation to drugs and biologics that are intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S.
Lastly, the company announced that it has appointed Heidi Henson, an industry veteran, to its Board of Directors. “I am pleased to welcome Heidi Henson to our board, where her extensive expertise in financial management and strategy will be a major asset to DrugCendR as we continue to advance the company programs.” said Erkki Ruoslahti, M.D., Ph.D., Founder, President, Chief Executive Officer and Chairman of DrugCendR. Mrs Henson, an independent board member, is the Chief Financial Officer of Respivant Biosciences. Her previous experience includes serving as the Chief Financial Officer of Kura Oncology and Wellspring Bioscience.
PRESS
ARCHIVES
- October 2019 (1)
- August 2019 (2)
- June 2019 (1)
- April 2019 (1)
- March 2019 (1)
- February 2019 (1)
- January 2019 (1)
- November 2018 (1)
- October 2018 (1)
- September 2018 (1)
- August 2018 (2)
- March 2018 (1)
- January 2018 (2)
- November 2017 (3)
- October 2017 (2)
- August 2017 (1)
- July 2017 (1)
- May 2017 (2)
- April 2017 (1)
- March 2016 (1)